Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: Efficacy and potential mechanisms of resistance to CXCR4 inhibition

Edward Allan R Sison, Daniel Magoon, Li Li, Colleen E. Annesley, Rachel E. Rau, Donald Small, Patrick A Brown

Research output: Contribution to journalArticle

Abstract

In spite of advances in the treatment of pediatric acute lymphoblastic leukemia (ALL), a significant number of children with ALL are not cured of their disease. We and others have shown that signaling from the bone marrow microenvironment confers therapeutic resistance, and that the interaction between CXCR4 and stromal cell-derived factor-1 (SDF-1 or CXCL12) is a key mediator of this effect. We demonstrate that ALL cells that upregulate surface CXCR4 in response to chemotherapy treatment are protected from chemotherapy-induced apoptosis when co-cultured with bone marrow stroma. Treatment with the CXCR4 inhibitor plerixafor diminishes stromal protection and confers chemosensitivity. Using xenograft models of high-risk pediatric ALL, plerixafor plus chemotherapy induces significantly decreased leukemic burden, compared to chemotherapy alone. Further, treatment with plerixafor and chemotherapy influences surface expression of CXCR4, VLA-4, and CXCR7 in surviving ALL blasts. Finally, prolonged exposure of ALL blasts to plerixafor leads to a persistent increase in surface CXCR4 expression, along with modulation of surface expression of additional adhesion molecules, and enhanced SDF-1a-induced chemotaxis, findings that may have implications for therapeutic resistance. Our results suggest that while CXCR4 inhibition may prove useful in ALL, further study is needed to understand the full effects of targeting the leukemic microenvironment.

Original languageEnglish (US)
Pages (from-to)8947-8958
Number of pages12
JournalOncotarget
Volume5
Issue number19
StatePublished - 2014

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Drug Therapy
Therapeutics
Bone Marrow
Integrin alpha4beta1
Chemokine CXCL12
Chemotaxis
JM 3100
Inhibition (Psychology)
Heterografts
Up-Regulation
Apoptosis

Keywords

  • Acute lymphoblastic leukemia
  • AMD3100
  • CXCR4
  • Microenvironment
  • Pediatric
  • Plerixafor

ASJC Scopus subject areas

  • Oncology

Cite this

Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia : Efficacy and potential mechanisms of resistance to CXCR4 inhibition. / Sison, Edward Allan R; Magoon, Daniel; Li, Li; Annesley, Colleen E.; Rau, Rachel E.; Small, Donald; Brown, Patrick A.

In: Oncotarget, Vol. 5, No. 19, 2014, p. 8947-8958.

Research output: Contribution to journalArticle

@article{3b294ce92e0446ed9a87ecf179eb1e0e,
title = "Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: Efficacy and potential mechanisms of resistance to CXCR4 inhibition",
abstract = "In spite of advances in the treatment of pediatric acute lymphoblastic leukemia (ALL), a significant number of children with ALL are not cured of their disease. We and others have shown that signaling from the bone marrow microenvironment confers therapeutic resistance, and that the interaction between CXCR4 and stromal cell-derived factor-1 (SDF-1 or CXCL12) is a key mediator of this effect. We demonstrate that ALL cells that upregulate surface CXCR4 in response to chemotherapy treatment are protected from chemotherapy-induced apoptosis when co-cultured with bone marrow stroma. Treatment with the CXCR4 inhibitor plerixafor diminishes stromal protection and confers chemosensitivity. Using xenograft models of high-risk pediatric ALL, plerixafor plus chemotherapy induces significantly decreased leukemic burden, compared to chemotherapy alone. Further, treatment with plerixafor and chemotherapy influences surface expression of CXCR4, VLA-4, and CXCR7 in surviving ALL blasts. Finally, prolonged exposure of ALL blasts to plerixafor leads to a persistent increase in surface CXCR4 expression, along with modulation of surface expression of additional adhesion molecules, and enhanced SDF-1a-induced chemotaxis, findings that may have implications for therapeutic resistance. Our results suggest that while CXCR4 inhibition may prove useful in ALL, further study is needed to understand the full effects of targeting the leukemic microenvironment.",
keywords = "Acute lymphoblastic leukemia, AMD3100, CXCR4, Microenvironment, Pediatric, Plerixafor",
author = "Sison, {Edward Allan R} and Daniel Magoon and Li Li and Annesley, {Colleen E.} and Rau, {Rachel E.} and Donald Small and Brown, {Patrick A}",
year = "2014",
language = "English (US)",
volume = "5",
pages = "8947--8958",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "19",

}

TY - JOUR

T1 - Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia

T2 - Efficacy and potential mechanisms of resistance to CXCR4 inhibition

AU - Sison, Edward Allan R

AU - Magoon, Daniel

AU - Li, Li

AU - Annesley, Colleen E.

AU - Rau, Rachel E.

AU - Small, Donald

AU - Brown, Patrick A

PY - 2014

Y1 - 2014

N2 - In spite of advances in the treatment of pediatric acute lymphoblastic leukemia (ALL), a significant number of children with ALL are not cured of their disease. We and others have shown that signaling from the bone marrow microenvironment confers therapeutic resistance, and that the interaction between CXCR4 and stromal cell-derived factor-1 (SDF-1 or CXCL12) is a key mediator of this effect. We demonstrate that ALL cells that upregulate surface CXCR4 in response to chemotherapy treatment are protected from chemotherapy-induced apoptosis when co-cultured with bone marrow stroma. Treatment with the CXCR4 inhibitor plerixafor diminishes stromal protection and confers chemosensitivity. Using xenograft models of high-risk pediatric ALL, plerixafor plus chemotherapy induces significantly decreased leukemic burden, compared to chemotherapy alone. Further, treatment with plerixafor and chemotherapy influences surface expression of CXCR4, VLA-4, and CXCR7 in surviving ALL blasts. Finally, prolonged exposure of ALL blasts to plerixafor leads to a persistent increase in surface CXCR4 expression, along with modulation of surface expression of additional adhesion molecules, and enhanced SDF-1a-induced chemotaxis, findings that may have implications for therapeutic resistance. Our results suggest that while CXCR4 inhibition may prove useful in ALL, further study is needed to understand the full effects of targeting the leukemic microenvironment.

AB - In spite of advances in the treatment of pediatric acute lymphoblastic leukemia (ALL), a significant number of children with ALL are not cured of their disease. We and others have shown that signaling from the bone marrow microenvironment confers therapeutic resistance, and that the interaction between CXCR4 and stromal cell-derived factor-1 (SDF-1 or CXCL12) is a key mediator of this effect. We demonstrate that ALL cells that upregulate surface CXCR4 in response to chemotherapy treatment are protected from chemotherapy-induced apoptosis when co-cultured with bone marrow stroma. Treatment with the CXCR4 inhibitor plerixafor diminishes stromal protection and confers chemosensitivity. Using xenograft models of high-risk pediatric ALL, plerixafor plus chemotherapy induces significantly decreased leukemic burden, compared to chemotherapy alone. Further, treatment with plerixafor and chemotherapy influences surface expression of CXCR4, VLA-4, and CXCR7 in surviving ALL blasts. Finally, prolonged exposure of ALL blasts to plerixafor leads to a persistent increase in surface CXCR4 expression, along with modulation of surface expression of additional adhesion molecules, and enhanced SDF-1a-induced chemotaxis, findings that may have implications for therapeutic resistance. Our results suggest that while CXCR4 inhibition may prove useful in ALL, further study is needed to understand the full effects of targeting the leukemic microenvironment.

KW - Acute lymphoblastic leukemia

KW - AMD3100

KW - CXCR4

KW - Microenvironment

KW - Pediatric

KW - Plerixafor

UR - http://www.scopus.com/inward/record.url?scp=84910028323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910028323&partnerID=8YFLogxK

M3 - Article

C2 - 25333254

AN - SCOPUS:84910028323

VL - 5

SP - 8947

EP - 8958

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 19

ER -